{"id":"lucinactant","rwe":[{"pmid":"37732036","year":"2023","title":"Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis.","finding":"","journal":"Archives of medical science : AMS","studyType":"Clinical Study"},{"pmid":"31436493","year":"2020","title":"Deposition of Aerosolized Lucinactant in Nonhuman Primates.","finding":"","journal":"Journal of aerosol medicine and pulmonary drug delivery","studyType":"Clinical Study"},{"pmid":"30744318","year":"2019","title":"Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future.","finding":"","journal":"Korean journal of pediatrics","studyType":"Clinical Study"},{"pmid":"28877030","year":"2017","title":"Radiation Mitigating Properties of Intranasally Administered KL(4) Surfactant in a Murine Model of Radiation-Induced Lung Damage.","finding":"","journal":"Radiation research","studyType":"Clinical Study"},{"pmid":"23473590","year":"2013","title":"Lucinactant for the prevention of respiratory distress syndrome in premature infants.","finding":"","journal":"Expert review of clinical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"lucinactant","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Respiratory distress syndrome in the newborn","category":"indication"},{"label":"Discovery Labs","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Discovery Labs","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LUCINACTANT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:00:46.435207+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lucinactant","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:00:54.336140+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:00:53.063850+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LUCINACTANT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:00:53.778075+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1963685/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:00:54.234401+00:00"}},"allNames":"surfaxin","offLabel":[],"synonyms":["lucinactant","surfaxin","KL-surfactant","KL4-surfactant"],"timeline":[{"date":"2012-03-06","type":"positive","source":"DrugCentral","milestone":"FDA approval (Discovery Labs)"}],"approvals":[{"date":"2012-03-06","orphan":false,"company":"DISCOVERY LABS","regulator":"FDA"}],"brandName":"Surfaxin","ecosystem":[{"indication":"Respiratory distress syndrome in the newborn","otherDrugs":[{"name":"beractant","slug":"beractant","company":"Abbvie"},{"name":"calfactant","slug":"calfactant","company":"Ony"},{"name":"cetyl alcohol","slug":"cetyl-alcohol","company":"Glaxosmithkline"},{"name":"colfosceril palmitate","slug":"colfosceril-palmitate","company":"Glaxosmithkline"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"lucinactant","explanation":"","oneSentence":"","technicalDetail":"Surfaxin, a lucinactant, functions by reducing the surface tension of the alveolar lining fluid, thereby facilitating lung expansion and gas exchange in newborns with Respiratory Distress Syndrome."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lucinactant","title":"Lucinactant","extract":"Lucinactant is a liquid medication used to treat infant respiratory distress syndrome. It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant, calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.","wiki_history":"==History==\nThe scientific groundwork for lucinactant was laid in the laboratory of Charles Cochrane at The Scripps Research Institute in the 1990s. The drug was then developed by Discovery Laboratories of Warrington, PA. The path through the approval process was unusually long, reflecting in part challenges in the manufacturing process that needed to be addressed before approval was granted."},"commercial":{"launchDate":"2012","_launchSource":"DrugCentral (FDA 2012-03-06, DISCOVERY LABS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4232","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LUCINACTANT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LUCINACTANT","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Lucinactant","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:25:57.498300","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:56.116615+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"lucinactant","indications":{"approved":[{"name":"Respiratory distress syndrome in the newborn","source":"DrugCentral","snomedId":46775006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT04389671","phase":"PHASE2","title":"The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2021-01-05","conditions":["COVID-19","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)"],"enrollment":20,"completionDate":"2022-02-20"},{"nctId":"NCT04264156","phase":"PHASE2","title":"A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2020-04-18","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":12,"completionDate":"2021-03-28"},{"nctId":"NCT02636868","phase":"PHASE2","title":"The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2015-12","conditions":["Respiratory Distress Syndrome"],"enrollment":221,"completionDate":"2019-08-06"},{"nctId":"NCT02528318","phase":"PHASE2","title":"Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2015-08","conditions":["Respiratory Distress Syndrome"],"enrollment":48,"completionDate":"2017-08-11"},{"nctId":"NCT00215553","phase":"PHASE2","title":"KL₄Surfactant Treatment in Patients With ARDS","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2001-05","conditions":["Acute Respiratory Distress Syndrome"],"enrollment":124,"completionDate":"2006-02"},{"nctId":"NCT02074059","phase":"PHASE2","title":"Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2014-02","conditions":["Respiratory Distress Syndrome"],"enrollment":80,"completionDate":"2015-11"},{"nctId":"NCT00934362","phase":"PHASE2","title":"Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-10","conditions":["Cystic Fibrosis"],"enrollment":16,"completionDate":"2010-08"},{"nctId":"NCT00807235","phase":"PHASE2","title":"Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2005-01","conditions":["Respiratory Distress Syndrome"],"enrollment":17,"completionDate":"2005-09"},{"nctId":"NCT00215540","phase":"PHASE2","title":"SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2005-02","conditions":["Respiratory Distress Syndrome, Newborn","Premature Birth","Bronchopulmonary Dysplasia"],"enrollment":136,"completionDate":"2006-07"},{"nctId":"NCT00578734","phase":"PHASE2","title":"Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old","status":"COMPLETED","sponsor":"Windtree Therapeutics","startDate":"2007-06","conditions":["Acute Hypoxemic Respiratory Failure"],"enrollment":165,"completionDate":"2010-04"},{"nctId":"NCT00004500","phase":"PHASE3","title":"Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome","status":"TERMINATED","sponsor":"Windtree Therapeutics","startDate":"2000-03","conditions":["Meconium Aspiration"],"enrollment":69,"completionDate":"2004-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"188307","NDDF":"014225","UNII":"5BSH2G9BH8","RXNORM":"1293254","UMLSCUI":"C1609686","chemblId":"CHEMBL1963685","ChEMBL_ID":"CHEMBL1963685","KEGG_DRUG":"D04792","DRUGBANK_ID":"DB04897","PUBCHEM_CID":"155886531","SNOMEDCT_US":"418166001","MESH_SUPPLEMENTAL_RECORD_UI":"C502722"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2012-","companyName":"Discovery Labs","relationship":"Original Developer"}],"publicationCount":38,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"originalDeveloper":"Discovery Labs","recentPublications":[{"date":"2023","pmid":"37732036","title":"Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis.","journal":"Archives of medical science : AMS"},{"date":"2020 Feb","pmid":"31436493","title":"Deposition of Aerosolized Lucinactant in Nonhuman Primates.","journal":"Journal of aerosol medicine and pulmonary drug delivery"},{"date":"2019 May","pmid":"30744318","title":"Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future.","journal":"Korean journal of pediatrics"},{"date":"2017 Nov","pmid":"28877030","title":"Radiation Mitigating Properties of Intranasally Administered KL(4) Surfactant in a Murine Model of Radiation-Induced Lung Damage.","journal":"Radiation research"},{"date":"2013 Mar","pmid":"23473590","title":"Lucinactant for the prevention of respiratory distress syndrome in premature infants.","journal":"Expert review of clinical pharmacology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Discovery Labs","companyId":"discovery-labs","modality":"Small Molecule","firstApprovalDate":"2012","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-03-06T00:00:00.000Z","mah":"DISCOVERY LABS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:56.116615+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}